NCT03128515View on ClinicalTrials.gov

Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas

PHASE3CompletedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

July 26, 2017

Primary Completion Date

April 7, 2019

Study Completion Date

January 28, 2020

Conditions
Sickle Cell AnemiaSickle Cell DiseaseMalaria
Interventions
DRUG

Hydroxyurea

Administered once a day in tablet form (100mg or scored 1000mg) for 24 months

Trial Locations (1)

Unknown

Mulago Hospital Sickle Cell Clinic, Kampala

All Listed Sponsors
collaborator

Doris Duke Charitable Foundation

OTHER

collaborator

Makerere University

OTHER

collaborator

Mulago Hospital, Uganda

OTHER

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

lead

Indiana University

OTHER

NCT03128515 - Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas | Biotech Hunter | Biotech Hunter